Passage Bio, Inc.

Passage Bio, Inc.

NNASDAQ:PASG
4.13
USD
-0.12
(-2.82%)
-10.33EPS
14.48MMarket Cap
Mar 08Next Earn

Total Valuation

USD

As of September 30, 2026, Passage Bio, Inc. carries a market capitalization of 14.48M, placing it among publicly traded companies globally. Its enterprise value stands at -5.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap14.48M
Enterprise Value-5.68M

Important Dates

Passage Bio, Inc.'s next confirmed earnings release is scheduled for March 8, 2027.

Earnings Date3/8/2027

Share Statistics

As of September 30, 2026, Passage Bio, Inc. has 3.22M shares outstanding.

Shares Outstanding3.22M

Valuation Ratios

These figures are as of September 30, 2026.

PB Ratio289.60
P/TBV Ratio289.60
P/FCF Ratio-0.44
P/OCF Ratio-0.44

Financial Position

As of September 30, 2026, Passage Bio, Inc. maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

Current Ratio1.00
Quick Ratio0.97

Financial Efficiency

Over the twelve months ended September 30, 2026, Passage Bio, Inc. posted a negative return on equity (ROE) of -212.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -69.68, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 24.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-212.27
Return on Assets (ROA)-69.68
Employee Count24.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Passage Bio, Inc.'s stock has declined approximately 53.33% over the past 52 weeks. The 50-day moving average sits at 4.10, while the 200-day moving average is 5.78.

52-Week Price Change-53.33%
50-Day Moving Average4.10
200-Day Moving Average5.78

Income Statement

USD

Over the twelve months ended September 30, 2026, Passage Bio, Inc. generated - - in revenue and converted that into -33.08M in net income, yielding earnings per share of -10.33. EBITDA reached -34.98M, while operating income came in at -34.38M.

Operating Income-34.38M
Pretax Income-33.08M
Net Income-33.08M
EBITDA-34.98M
EBIT-35.31M
Earnings Per Share (EPS)-10.33

Balance Sheet

USD

As of September 30, 2026, Passage Bio, Inc. holds 20.16M in cash and equivalents against - - in total debt, resulting in a net debt position of -20.16M. Total book value stands at 50,000.00, with working capital of 50,000.00 providing operational flexibility.

Cash & Cash Equivalents20.16M
Net Debt-20.16M
Equity (Book Value)50,000.00
Book Value Per Share0.02
Working Capital50,000.00

Cash Flow

USD

Passage Bio, Inc. produced -32.64M in operating cash flow over the twelve months ended September 30, 2026.

Operating Cash Flow-32.64M
Free Cash Flow-32.64M
FCF Per Share-10.19

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -226.43: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.06, meaning Passage Bio, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.06
FCF Yield-226.43

Stock Splits

Passage Bio, Inc.'s most recent stock split took place on July 14, 2025 with a 20:1 split ratio.

Last Split Date7/14/2025
Split Ratio20:1

Scores

As of September 30, 2026, Passage Bio, Inc. has an Altman Z-Score of -53.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-53.84